Achilles Therapeutics (ACHL)
(Delayed Data from NSDQ)
$0.92 USD
-0.02 (-2.10%)
Updated May 31, 2024 03:22 PM ET
After-Market: $0.94 +0.02 (2.17%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACHL 0.92 -0.02(-2.10%)
Will ACHL be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ACHL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACHL
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
ACHL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?
Waters (WAT) Walk-Up Solutions Boost Bioprocess Development
Other News for ACHL
Achilles Therapeutics Calls for AGM Participation
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Achilles Therapeutics announces research collaboration with Arcturus
Achilles Therapeutics receives Nasdaq notice for non-compliance
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement